A role for Danazol in chronic lymphocytic leukemia

Leukemia

Volumn 26, Issue 7, 2012, Pages 1684-1686

  Tung, S ^a,b   Spaner, D E ^a,b,c  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DEXAMETHASONE; FLUDARABINE; GLUCOCORTICOID;

ADULT; ANGIONEUROTIC EDEMA; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER STAGING; CASE REPORT; CELL KILLING; CHROMOSOME 11Q; CHRONIC LYMPHATIC LEUKEMIA; DRUG MEGADOSE; FATIGUE; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; LETTER; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL SURVIVAL; DANAZOL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 84863748634     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.386     Document Type: Letter

References (14)

1. Gribben JG, O'Brien S. Update on therapy of CLL. J Clin Oncol 2011; 29: 544-550.
2. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of CLL. Leukemia 2009; 23: 1779-1789.
3. Fontana V, Dudkiewicz P, Ahn ER, Horstman L, Ahn YS. Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD). Hematology 2011; 16: 90-94.
4. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274-281.
5. Morcavallo PS, Leonida A, Rossi G, Mingardi M, Martini M, Monguzzi R et al. Hereditary angioedema in oral surgery. J Oral Maxillofac Surg 2010; 68: 2307-2311.
6. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157: 561-569.
7. Spaner DE. Oral high-dose glucocorticoids and ofatumumab in flurarabineresistant chronic lymphocytic leukemia. Leukemia 2011; e-pub ahead of print 8 November 2011; doi:10.1038/leu.2011.329.
8. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory ITP. Blood 2007; 110: 3526-3531.
9. Shepherd J. Danazol and plasma lipoprotein metabolism. Int J Gynaecol Obstet 1995; 50(Suppl 1): S23-S26.
10. Alvarez G, Gó mez-Galicia D, Rodŕguez-Fragoso L, Marina V, Dorantes L, Sánchez-Alemán M et al. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann Hepatol 2011; 10: 458-468.
11. Matalliotakis I, Neonaki M, Koumantaki Y, Goumenou A, Kyriakou D, Koumantakis E. A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstet Gynecol 2000; 95: 810-813.
12. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive CLL. Blood 2011; 117: 2668-2680.
13. Tanaka T. Danazol regulates the functions of normal human endometrial stromal cell subpopulations by modifying endometrial cytokine networks. Int J Mol Med 2009; 23: 421-428.
14. Horstman L, Jy W, Arce M, Ahn YS. Danazol distribution in plasma and cell membranes as related to altered cell properties: implications for mechanism. Am J Hematol 1995; 50: 179-187.